Affymetrix, Inc.

Wellcome Trust Case Control Consortium and Affymetrix Expand World's Largest Study of Genetic Diseases

Published in Physician Law Weekly, August 13th, 2008

Affymetrix, Inc. (Nasdaq:AFFX) announced that the Wellcome Trust of Great Britain has awarded to Affymetrix the second phase of its Case Control Consortium (WTCCC) project, the world's largest-ever study of the genetics behind common diseases. The second phase will analyze the genetic information of 60,000 additional individuals, 30,000 of them with the Affymetrix(R) Genome-Wide Human SNP Array 6.0, plus 6,000 common controls.

Over the next year, 14 UK research groups will collaborate with the WTCCC to identify genetic contributions to 14 common diseases and drug responses, including schizophrenia, ulcerative colitis, psychosis, bacteriosis, pre-eclampsia and statin...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Physician Law Weekly

Source: Physician Law Weekly (2008-08-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry